Building on a Legacy of Hypertension Research

Mensah, George A.; Galis, Zorina S.; Fine, Lawrence J.; García, Melissa; Levy, Daniel; Gibbons, Gary H.

doi:10.1161/hypertensionaha.116.06582

Cited by 5 publications

(3 citation statements)

References 58 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In spite of remarkable achievements in HTN research, Mensah and colleagues at the National Heart Lung and Blood Institute recently emphasized that “hypertension remains the leading cause of global death and disability from heart disease and stroke and a major contributor to all-cause mortality worldwide.” 29 The growing health burden of HTN reinforces the need to understand mechanisms, diagnostic and therapeutic opportunities for prevention and treatment of HTN. From this perspective, our findings have important pathophysiologic and clinical implications in human HTN.…”

Section: Discussionmentioning

confidence: 99%

Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population

Cannone

Buglioni

Sangaralingham

et al. 2018

Mayo Clinic Proceedings

View full text Add to dashboard Cite

In this randomly selected general population cohort, aldosterone levels were higher in individuals with HTN compared with normotensive participants. Aldosterone levels increased with anti-HTN medication use. These findings also suggest a relative ANP deficiency with increasing aldosterone levels and anti-HTN drug use. These studies have pathophysiologic and therapeutic implications for targeting aldosterone in the clinical treatment of HTN.

show abstract

Section: Discussionmentioning

confidence: 99%

Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population

Cannone

Buglioni

Sangaralingham

et al. 2018

Mayo Clinic Proceedings

View full text Add to dashboard Cite

show abstract

“…clinical trials, epigenetics, obesity, role of microbiota in blood pressure regulation, epidemiology and prevention of cardiovascular disease). As recently reported, NHLBI is committed to maintaining a balanced portfolio of basic, translational clinical, and population science research (18). In its “strategic vision”, the Institute “…looks to its investigator community to identify mission-oriented strategic priorities and help chart the future together.” Currently, there are bidirectional translation gaps between the basic, clinical, and community domains.…”

Section: Establishing Future Hypertension Research Funding Prioritiesmentioning

confidence: 99%

Establishing Funding Priorities for Hypertension Research

Kotchen

2017

Hypertension

View full text Add to dashboard Cite

“…Dissemination and implementation (D & I) science, with its multilevel frameworks, outcomes, and designs, is geared toward increasing uptake and sustainment of evidence-based interventions (EBIs) for prevention, treatment, and control of hypertension [10–12], Suboptimal infrastructure and capacity in Rwanda hinders research and community knowledge for HTN control. Our U24 grant project funded by the National Heart, Lung, and Blood Institute (NHLBI) aims to develop late phase (T4) translational research capacity for control of hypertension in Rwanda through D & I research capacity building.…”

mentioning

confidence: 99%

Dissemination and Implementation Program in Hypertension in Rwanda: Report on Initial Training and Evaluation

Baumann

Mutabazi²,

Brown³

et al. 2019

View full text Add to dashboard Cite

Background: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide and in low-and middle-income countries, and hypertension (HTN) is a major risk factor for CVD. Although effective evidence-based interventions for control of HTN in high-income countries exist, implementation of these in low-and middle-income countries has been challenging due to limited capacity and infrastructure for latephase translational research. In Rwanda, the 2015 STEPS NCD (STEPwise Approach to Surveillance of Noncommunicable Diseases) risk survey reported an overall prevalence of HTN of 15% (95% confidence interval [CI]: 13.8 to 16.3) for those ages 15 to 64 years; prevalence increased with increasing age to 39% (95% CI: 35.7 to 43.1) for those ages 55 to 64 years; CVD was the third most common cause of mortality (7%). Suboptimal infrastructure and capacity in Rwanda hinders research and community knowledge for HTN control. Objectives: To address the issue of suboptimal capacity to implement evidence-based interventions in HTN, this project was designed with the following objectives: 1) to develop a regional needs assessment of infrastructure for dissemination and implementation (D & I) strategies for HTN-CVD control; 2) to develop HTN-CVD research capacity through creation of countrywide resources such as core research facilities and training in the fields of HTN-CVD, D & I, and biostatistics; and 3) to engage and train multiple stakeholders in D & I and HTN-CVD evidence-based interventions. Methods: A weeklong training program in HTN-CVD, biostatistics, and D & I was conducted in Rwanda in August 2018, and pre-and post-D & I training competency questionnaires were administered. Results: Questionnaire results show a statistically significant increase in D & I knowledge and skills as a result of training (full scale pre-to post-test scores: 2.12 AE 0.78 vs. 3.94 AE 0.42; p < 0.0001). Conclusions: Using principles of community engagement and train-the-trainer methods, we will continue to adapt guidelines and treatments for HTN-CVD developed in high-income countries to the context of Rwanda with the goal of establishing a sustainable platform to address the burden of disease from HTN-CVD.

show abstract

Building on a Legacy of Hypertension Research

Cited by 5 publications

References 58 publications

Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population

Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population

Establishing Funding Priorities for Hypertension Research

Dissemination and Implementation Program in Hypertension in Rwanda: Report on Initial Training and Evaluation

Contact Info

Product

Resources

About